Ascletis has dosed the first participant in its Phase III program for ASC30, an oral GLP-1 pill for chronic weight management, with topline data expected in 2028.
#Obesity #GLP1 #Biotech
Disclaimer: This is NOT a financial advice
Ascletis has dosed the first participant in its Phase III program for ASC30, an oral GLP-1 pill for chronic weight management, with topline data expected in 2028. #Obesity #GLP1 #Biotech Disclaimer: This is NOT a financial advice
0 vue
Publié le 02/09/2026 07:42
Ascletis has dosed the first participant in its Phase III program for ASC30, an oral GLP-1 pill for chronic weight management, with topline data expected in 2028.
#Obesity #GLP1 #Biotech
Disclaimer: This is NOT a financial advice
0 commentaire
?